AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 19473807 — intervention group
Group type: COMPARATOR
Intervention: Titanium acetabular component
Number of subjects: 17
Study 18951618 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin
Number of subjects: 55
Study 18951618 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast
Number of subjects: 55
Study 18951618 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study 16826390 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep sedation (continuous infusion of midazolam and fentanyl) without neuromuscular blockade
Number of subjects: 19
Study 16826390 — intervention group
Group type: COMPARATOR
Intervention: Paralysis induced by cis‐atracurium
Number of subjects: 19
Study 12641301 — intervention group
Group type: COMPARATOR
Intervention: Planned cesarean section
Number of subjects: 0
Study 12641301 — intervention group
Group type: EXPERIMENTAL
Intervention: Planned vaginal birth
Number of subjects: 0
Study 10915751 — intervention group
Group type: EXPERIMENTAL
Intervention: Famciclovir 500 mg 3 times daily
Number of subjects: 417
Study 10915751 — intervention group
Group type: EXPERIMENTAL
Intervention: Famciclovir 1.5 g once daily
Number of subjects: 417
Study 10915751 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 417
Study 8936892 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined pharmacologic and psychological intervention (Cl)
Number of subjects: 162
Study 8936892 — intervention group
Group type: COMPARATOR
Intervention: Pharmacologic only (PO)
Number of subjects: 162
Study 8936892 — intervention group
Group type: COMPARATOR
Intervention: Cross-sectional control (CC)
Number of subjects: 162
Study 1558500 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed primary wound closure
Number of subjects: 63
Study 1558500 — intervention group
Group type: COMPARATOR
Intervention: Immediate wound closure
Number of subjects: 63
Study 3155644 — intervention group
Group type: EXPERIMENTAL
Intervention: Synthetic thymosin alpha-1
Number of subjects: 62
Study 3155644 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study 3155644 — intervention group
Group type: EXPERIMENTAL
Intervention: RT
Number of subjects: 62
Study 31874879 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil
Number of subjects: 49
Study 31874879 — intervention group
Group type: COMPARATOR
Intervention: Pethidine
Number of subjects: 49
Study 28429577 — intervention group
Group type: EXPERIMENTAL
Intervention: Commercial provider (Weight Watchers)
Number of subjects: 268
Study 28429577 — intervention group
Group type: COMPARATOR
Intervention: Standard care (SC)
Number of subjects: 268
Study 26637570 — intervention group
Group type: EXPERIMENTAL
Intervention: CRSwNP
Number of subjects: 60
Study 26637570 — intervention group
Group type: EXPERIMENTAL
Intervention: CRSnNP
Number of subjects: 60
Study 26637570 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 60
Study 24030130 — intervention group
Group type: EXPERIMENTAL
Intervention: TEAM intervention (6-month intervention with scheduled visits, Brief Medication Questionnaires, and toolkits)
Number of subjects: 576
Study 24030130 — intervention group
Group type: COMPARATOR
Intervention: Control (patient information only)
Number of subjects: 576
Study 18638265 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-frequency pulsed current (Dermapulse)
Number of subjects: 39
Study 18638265 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study 16528696 — intervention group
Group type: EXPERIMENTAL
Intervention: Single media literacy lessons
Number of subjects: 237
Study 12958617 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerivastatin discontinuation
Number of subjects: 34
Study 12958617 — intervention group
Group type: COMPARATOR
Intervention: Simvastatin treatment
Number of subjects: 34
Study 12958617 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin after 60 days of diet
Number of subjects: 34
Study 10991852 — intervention group
Group type: EXPERIMENTAL
Intervention: Fosfomycin 4 g
Number of subjects: 6
Study 10991852 — intervention group
Group type: EXPERIMENTAL
Intervention: Fosfomycin 8 g
Number of subjects: 6
Study 8827693 — intervention group
Group type: EXPERIMENTAL
Intervention: Partially hydrogenated soybean oil-based stick margarine
Number of subjects: 8
Study 8827693 — intervention group
Group type: COMPARATOR
Intervention: Soybean oil
Number of subjects: 8
Study 8827693 — intervention group
Group type: EXPERIMENTAL
Intervention: Both diets
Number of subjects: 8
Study 1571681 — intervention group
Group type: EXPERIMENTAL
Intervention: Home based care (daily living programme)
Number of subjects: 189
Study 1571681 — intervention group
Group type: COMPARATOR
Intervention: Standard hospital care
Number of subjects: 189
Study 1571681 — intervention group
Group type: EXPERIMENTAL
Intervention: Home based care
Number of subjects: 189
Study 3899973 — intervention group
Group type: EXPERIMENTAL
Intervention: Benzydamine mouthwash
Number of subjects: 0
Study 3899973 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30596272 — intervention group
Group type: EXPERIMENTAL
Intervention: Implementation intention intervention
Number of subjects: 63
Study 30596272 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 63
Study 28866457 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholangioscopy-guided laser lithotripsy
Number of subjects: 60
Study 28866457 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy only
Number of subjects: 60
Study 27108819 — intervention group
Group type: EXPERIMENTAL
Intervention: Benzydamine hydrochloride gel
Number of subjects: 124
Study 27108819 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% lidocaine hydrochloride gel
Number of subjects: 124
Study 27108819 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% lidocaine hydrochloride spray
Number of subjects: 124
Study 27108819 — intervention group
Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 124
Study 24704135 — intervention group
Group type: EXPERIMENTAL
Intervention: Revised Contingent Voucher (RCV)
Number of subjects: 118
Study 24704135 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual Contingent Voucher (CV)
Number of subjects: 118
Study 24704135 — intervention group
Group type: COMPARATOR
Intervention: Non-Contingent Voucher (NCV)
Number of subjects: 118
Study 21824050 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab added to fludarabine and cyclophosphamide (R-FC)
Number of subjects: 0
Study 21824050 — intervention group
Group type: COMPARATOR
Intervention: Fludarabine and cyclophosphamide (FC)
Number of subjects: 0
Study 19640357 — intervention group
Group type: EXPERIMENTAL
Intervention: Nelfabiovir (Bakhtar Bioshimi, Iran) 250 mg
Number of subjects: 24
Study 19640357 — intervention group
Group type: COMPARATOR
Intervention: Viracept (Roche, Germany) 250 mg
Number of subjects: 24
Study 17461873 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary enalaprilat (50 microg)
Number of subjects: 22
Study 17461873 — intervention group
Group type: COMPARATOR
Intervention: Placebo/saline (PL)
Number of subjects: 22
Study 15190828 — intervention group
Group type: EXPERIMENTAL
Intervention: nCPAP treatment from 22:00 to 6:00 per night for 1 month
Number of subjects: 27
Study 15190828 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 27
Study 11777513 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-assisted virtual urethral pressure profile
Number of subjects: 61
Study 9821925 — intervention group
Group type: EXPERIMENTAL
Intervention: Ototopical antibiotics plus topical phenylephrine
Number of subjects: 208
Study 9821925 — intervention group
Group type: COMPARATOR
Intervention: Ototopical antibiotics
Number of subjects: 208
Study 9221158 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1 mg/kg of moradole
Number of subjects: 10
Study 9221158 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 1785268 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction of labor (n = 139)
Number of subjects: 369
Study 1785268 — intervention group
Group type: COMPARATOR
Intervention: Conservative management (n = 138)
Number of subjects: 369
Study 6796322 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol 20 mg orally four times daily for 5 days
Number of subjects: 9
Study 6796322 — intervention group
Group type: COMPARATOR
Intervention: Placebo four times daily for 5 days
Number of subjects: 9
Study 31028447 — intervention group
Group type: EXPERIMENTAL
Intervention: Model with radiomic features combined with dosimetric parameters
Number of subjects: 94
Study 31028447 — intervention group
Group type: COMPARATOR
Intervention: Radiomic features alone
Number of subjects: 94
Study 28948326 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient navigation intervention for elective surgery in the mountain group
Number of subjects: 0
Study 28948326 — intervention group
Group type: COMPARATOR
Intervention: Control group from mountainous area
Number of subjects: 0
Study 28948326 — intervention group
Group type: COMPARATOR
Intervention: Control group from plains
Number of subjects: 0
Study 23484369 — intervention group
Group type: EXPERIMENTAL
Intervention: Polaprezinc (zinc agent)
Number of subjects: 219
Study 23484369 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 219
Study 22159931 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin 1,200 mg day-1
Number of subjects: 90
Study 22159931 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin 300 mg day-1
Number of subjects: 90
Study 22159931 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study 18579230 — intervention group
Group type: EXPERIMENTAL
Intervention: metoprolol+felodipine-placebo (MP group, n=23)
Number of subjects: 63
Study 18579230 — intervention group
Group type: EXPERIMENTAL
Intervention: metoprolol+felodipine (MF group, n=20)
Number of subjects: 63
Study 18579230 — intervention group
Group type: EXPERIMENTAL
Intervention: metoprolol-placebo+felodipine-placebo (PP group, n=20)
Number of subjects: 63
Study 17956454 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin sensitivity measured by the euglycaemic clamp
Number of subjects: 818
Study 17956454 — intervention group
Group type: EXPERIMENTAL
Intervention: HOMA‐IR
Number of subjects: 818
Study 17956454 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasting insulin
Number of subjects: 818
Study 17956454 — intervention group
Group type: EXPERIMENTAL
Intervention: HOMA‐IR and fasting insulin
Number of subjects: 818
Study 17956454 — intervention group
Group type: EXPERIMENTAL
Intervention: HOMA‐IR and insulin sensitivity measured with the euglycaemic clamp
Number of subjects: 818
Study 15119916 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-acting risperidone 25 mg
Number of subjects: 282
Study 15119916 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-acting risperidone 50 mg
Number of subjects: 282
Study 15119916 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-acting risperidone 75 mg
Number of subjects: 282
Study 15119916 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 282
Study 11340827 — intervention group
Group type: EXPERIMENTAL
Intervention: Preschool speech and language therapy services
Number of subjects: 68
Study 9279482 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured exercise and support programme
Number of subjects: 26
Study 9279482 — intervention group
Group type: COMPARATOR
Intervention: Standard outpatient clinic education
Number of subjects: 26
Study 9279482 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased activity over 6 months
Number of subjects: 26
Study 9279482 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased activity over 12 months
Number of subjects: 26
Study 7920892 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone or GnRH treatment
Number of subjects: 15
Study 7920892 — intervention group
Group type: COMPARATOR
Intervention: Control group (normal men)
Number of subjects: 15
Study 2823864 — intervention group
Group type: EXPERIMENTAL
Intervention: Extruded product
Number of subjects: 7
Study 2823864 — intervention group
Group type: COMPARATOR
Intervention: Bran-gluten-starch mixture
Number of subjects: 7
Study 29471466 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3 ppm ozone for 2 h during intermittent exercise
Number of subjects: 32
Study 29471466 — intervention group
Group type: COMPARATOR
Intervention: Filtered air (FA)
Number of subjects: 32
Study 28010832 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture at CV-12 (Zhongwan)
Number of subjects: 36
Study 28010832 — intervention group
Group type: COMPARATOR
Intervention: Placebo control (sham point on the right side of the abdomen)
Number of subjects: 36
Study 25193416 — intervention group
Group type: EXPERIMENTAL
Intervention: External fixation
Number of subjects: 110
Study 25193416 — intervention group
Group type: COMPARATOR
Intervention: Volar locking plates
Number of subjects: 110
Study 25193416 — intervention group
Group type: EXPERIMENTAL
Intervention: External fixation (patients aged <50 years)
Number of subjects: 110
Study 25193416 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 110
Study 23174047 — intervention group
Group type: EXPERIMENTAL
Intervention: clindamycin 1%/BPO 5% gel
Number of subjects: 48
Study 23174047 — intervention group
Group type: COMPARATOR
Intervention: adapalene 0.1%/BPO 2.5% gel
Number of subjects: 48
Study 20158589 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus 0.03% ointment, applied twice weekly for 12 months
Number of subjects: 153
Study 20158589 — intervention group
Group type: COMPARATOR
Intervention: Standard flare-only therapy
Number of subjects: 153
Study 18544020 — intervention group
Group type: EXPERIMENTAL
Intervention: tgAAC09 at 3 x 10(9) DNase resistant particles (DRP) (n = 16)
Number of subjects: 80
Study 18544020 — intervention group
Group type: EXPERIMENTAL
Intervention: tgAAC09 at 3 x 10(10) DRP (n = 23)
Number of subjects: 80
Study 18544020 — intervention group
Group type: EXPERIMENTAL
Intervention: tgAAC09 at 3 x 10(11) DRP (n = 25)
Number of subjects: 80
Study 18544020 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 16)
Number of subjects: 80
Study 18544020 — intervention group
Group type: EXPERIMENTAL
Intervention: tgAAC09 boost dose of 3 x 10(11) DRP
Number of subjects: 80
Study 18544020 — intervention group
Group type: EXPERIMENTAL
Intervention: tgAAC09 (overall)
Number of subjects: 80
Study 16174195 — intervention group
Group type: EXPERIMENTAL
Intervention: Interdisciplinary teamwork
Number of subjects: 0
Study 16174195 — intervention group
Group type: EXPERIMENTAL
Intervention: Leadership in interdisciplinary teams
Number of subjects: 0
Study 12357317 — intervention group
Group type: EXPERIMENTAL
Intervention: T-fastener gastropexy
Number of subjects: 90
Study 12357317 — intervention group
Group type: COMPARATOR
Intervention: No gastropexy
Number of subjects: 90
Study 10521843 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparative genomic hybridization (CGH) with DOP-PCR amplified DNA
Number of subjects: 0
Study 10521843 — intervention group
Group type: COMPARATOR
Intervention: Normal genomic DNA that underwent DOP-PCR
Number of subjects: 0
Study 7537110 — intervention group
Group type: COMPARATOR
Intervention: Interleukin-6 (IL-6) administered at escalating doses from 0.5 to 10 micrograms/kg/d during chemotherapy cycles 2 to 6.
Number of subjects: 3
Study 7537110 — intervention group
Group type: COMPARATOR
Intervention: Interleukin-6 (IL-6) administered before chemotherapy.
Number of subjects: 3
Study 7537110 — intervention group
Group type: COMPARATOR
Intervention: Interleukin-6 (IL-6) administered during chemotherapy.
Number of subjects: 3
Study 7537110 — intervention group
Group type: COMPARATOR
Intervention: Interleukin-6 (IL-6) administered after chemotherapy.
Number of subjects: 3
Study 7537110 — intervention group
Group type: COMPARATOR
Intervention: Interleukin-6 (IL-6) administered at escalating doses up to 10 micrograms/kg/d.
Number of subjects: 3
Study 1800252 — intervention group
Group type: EXPERIMENTAL
Intervention: Incontinence training program
Number of subjects: 166
Study 7049582 — intervention group
Group type: EXPERIMENTAL
Intervention: Active treatment (hydrochlorothiazide plus triamterene, with the addition of methyldopa if necessary)
Number of subjects: 0
Study 7049582 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30836896 — intervention group
Group type: EXPERIMENTAL
Intervention: Culling of badgers for disease control
Number of subjects: 0
Study 27553029 — intervention group
Group type: EXPERIMENTAL
Intervention: Winning the lottery ($100 cash grant)
Number of subjects: 0
Study 27553029 — intervention group
Group type: COMPARATOR
Intervention: Control group (eligible non-winners)
Number of subjects: 0
Study 26684265 — intervention group
Group type: EXPERIMENTAL
Intervention: Cycle ergometer training (PD-C)
Number of subjects: 29
Study 26684265 — intervention group
Group type: COMPARATOR
Intervention: Treadmill training (PD-T)
Number of subjects: 29
Study 25351765 — intervention group
Group type: EXPERIMENTAL
Intervention: Electro-acupuncture (EA)
Number of subjects: 243
Study 25351765 — intervention group
Group type: EXPERIMENTAL
Intervention: Mosapride (M)
Number of subjects: 243
Study 25351765 — intervention group
Group type: COMPARATOR
Intervention: Mosapride & Sham Electro-acupuncture (MS)
Number of subjects: 243
Study 22740305 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.25 % povidone-iodine (PI) combined with 0.5 % topical levofloxacin (LVFX)
Number of subjects: 100
Study 22740305 — intervention group
Group type: COMPARATOR
Intervention: 5 % povidone-iodine (PI)
Number of subjects: 100
Study 19127161 — intervention group
Group type: EXPERIMENTAL
Intervention: Injection therapy (corticosteroids, local anesthetics, and other drugs)
Number of subjects: 1179
Study 19127161 — intervention group
Group type: COMPARATOR
Intervention: Injection therapy
Number of subjects: 1179
Study 18077809 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (16 mg twice daily for 4 days)
Number of subjects: 465
Study 18077809 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 465
Study 18077809 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ceftriaxone (2 g twice daily for 10 days)
Number of subjects: 465
Study 18077809 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular ceftriaxone (2 g twice daily for 10 days)
Number of subjects: 465
Study 15231553 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine 10-60 mg/day
Number of subjects: 54
Study 15231553 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study 11181655 — intervention group
Group type: COMPARATOR
Intervention: CMF plus placebo
Number of subjects: 2008
Study 11181655 — intervention group
Group type: EXPERIMENTAL
Intervention: CMF plus TAM
Number of subjects: 2008
Study 11181655 — intervention group
Group type: COMPARATOR
Intervention: AC plus placebo
Number of subjects: 2008
Study 11181655 — intervention group
Group type: EXPERIMENTAL
Intervention: AC plus TAM
Number of subjects: 2008
Study 9702843 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous itraconazole (200 mg as a 1-hour infusion twice daily for 2 days, then 200 mg once daily for 5 days)
Number of subjects: 30
Study 9702843 — intervention group
Group type: COMPARATOR
Intervention: Itraconazole capsules (200 mg once daily for 28 days)
Number of subjects: 30
Study 9702843 — intervention group
Group type: EXPERIMENTAL
Intervention: Itraconazole capsules (200 mg twice daily for 28 days)
Number of subjects: 30
Study 9702843 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous itraconazole followed by itraconazole capsules twice daily
Number of subjects: 30
Study 7986124 — intervention group
Group type: EXPERIMENTAL
Intervention: Frequency-doubled Q-switched Nd: YAG laser (532 nm, 2.0-mm spot size, 10 nanoseconds) at fluences of 2, 3, 4, or 5 J/cm2
Number of subjects: 49
Study 7986124 — intervention group
Group type: EXPERIMENTAL
Intervention: Frequency-doubled Q-switched Nd: YAG laser (532 nm)
Number of subjects: 49
Study 3202422 — intervention group
Group type: EXPERIMENTAL
Intervention: Inspiratory muscle training (IMT) with a pressure threshold breathing device at 30% of maximal inspiratory pressure (Plmax)
Number of subjects: 22
Study 3202422 — intervention group
Group type: COMPARATOR
Intervention: Inspiratory muscle training (IMT) with a pressure threshold breathing device at 15% of maximal inspiratory pressure (Plmax)
Number of subjects: 22
Study 30885281 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic assisted coblation adenoidectomy
Number of subjects: 60
Study 30885281 — intervention group
Group type: COMPARATOR
Intervention: Conventional cold curettage adenoidectomy
Number of subjects: 60
Study 28693439 — intervention group
Group type: EXPERIMENTAL
Intervention: Tapentadol
Number of subjects: 266
Study 28693439 — intervention group
Group type: COMPARATOR
Intervention: Oxycodone/naloxone
Number of subjects: 266
Study 25947187 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated internet addiction prevention program
Number of subjects: 56
Study 25947187 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 56
Study 24115820 — intervention group
Group type: EXPERIMENTAL
Intervention: Grasper type scissors (GTS)
Number of subjects: 76
Study 24115820 — intervention group
Group type: COMPARATOR
Intervention: Hook knife plus coagrasper (HKC)
Number of subjects: 76
Study 21454978 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine mouthwash for 2 weeks (Group A)
Number of subjects: 105
Study 21454978 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic yogurt containing Lactobacillus rhamnosus GG (LGG) for 3 weeks (Group B)
Number of subjects: 105
Study 21454978 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine followed by probiotic yogurt (Group C)
Number of subjects: 105
Study 18093113 — intervention group
Group type: EXPERIMENTAL
Intervention: Familiar identities (parents, teachers)
Number of subjects: 153
Study 18093113 — intervention group
Group type: COMPARATOR
Intervention: Unfamiliar identities (strangers)
Number of subjects: 153
Study 18093113 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic expressions of five emotions (happy, sad, anger, fear, disgust)
Number of subjects: 153
Study 16564254 — intervention group
Group type: EXPERIMENTAL
Intervention: L-arginine (7.5 g in 500 mL of cardioplegic solution)
Number of subjects: 65
Study 16564254 — intervention group
Group type: COMPARATOR
Intervention: Control (group B)
Number of subjects: 65
Study 14602763 — intervention group
Group type: EXPERIMENTAL
Intervention: TRIAC (19.6 micro g/kg)
Number of subjects: 36
Study 14602763 — intervention group
Group type: COMPARATOR
Intervention: L-T4 (1.7 microg/kg)
Number of subjects: 36
Study 14602763 — intervention group
Group type: EXPERIMENTAL
Intervention: TRIAC
Number of subjects: 36